<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03310957</url>
  </required_header>
  <id_info>
    <org_study_id>SGNLVA-002</org_study_id>
    <secondary_id>KEYNOTE 721</secondary_id>
    <nct_id>NCT03310957</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer</brief_title>
  <official_title>Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination With Pembrolizumab for First-Line Treatment of Patients With Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Genetics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seattle Genetics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies SGN-LIV1A in combination with pembrolizumab to find out what their side
      effects are and if they work for patients with triple-negative breast cancer that has spread
      to other parts of the body. Patients will be given both experimental drugs every 3 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary goal of this study is to evaluate the combination of SGN-LIV1A, which targets
      LIV-1- expressing tumor cells, with the checkpoint inhibitor pembrolizumab for patients with
      unresectable locally-advanced or metastatic triple-negative breast cancer. These two drugs
      act through distinct and possibly complementary modes of action.

      This is a single-arm, open-label, multicenter trial. Patients given SGN-LIV1A and
      pembrolizumab in Part A will be monitored for frequency of dose-limiting toxicities to
      determine if SGN-LIV1A dosing should be de-escalated before opening the expansion in Part B.
      In addition to safety measures, objective response rate, progression-free survival, overall
      survival, and other efficacy outcomes will be assessed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2018</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmed objective response rate</measure>
    <time_frame>Up to 18 weeks following last dose</time_frame>
    <description>Confirmed ORR as determined by investigator according to RECIST v 1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Through 1 month following last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of laboratory abnormalities</measure>
    <time_frame>Through 1 month following last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicities</measure>
    <time_frame>Through 1 month following last dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to 2.5 years following last dose</time_frame>
    <description>DOR as determined by investigator according to RECIST v 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>Up to 2.5 years following last dose</time_frame>
    <description>Proportion of patients with complete response (CR), partial response (PR), or stable disease (SD) as determined by investigator according to RECIST v 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to 2.5 years following last dose</time_frame>
    <description>PFS as determined by investigator according to RECIST v 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 2.5 years following last dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>SGN-LIV1A plus pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SGN-LIV1A followed by pembrolizumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGN-LIV1A</intervention_name>
    <description>IV infusion every 3 weeks</description>
    <arm_group_label>SGN-LIV1A plus pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>IV infusion every 3 weeks</description>
    <arm_group_label>SGN-LIV1A plus pembrolizumab</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metastatic or locally-advanced, histologically documented TNBC (absence of HER2, ER,
             and PR expression)

          -  Have not previously received therapy for the treatment of unresectable LA/M breast
             cancer

          -  At least 12 months since prior treatment with curative intent and recurrence

          -  At least 1 tumor 10mm in diameter or greater OR lymph node of at least 15 mm in short
             axis

          -  ECOG performance status of 0 or 1

          -  Able to provide biopsy tissue for biomarker analysis

          -  Meet baseline laboratory data criteria

          -  Not pregnant. Must agree not to become pregnant until at least 6 months after ceasing
             study treatment

        Exclusion Criteria:

          -  Prior immune-oncology therapy

          -  Pre-existing neuropathy of at least Grade 2

          -  Radiological evidence of CNS metastases

          -  Active autoimmune disease requiring systemic treatment within the past 2 years

          -  History of interstitial lung disease

          -  Current pneumonitis or history of pneumonitis requiring steroids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hong Ren, MD, MS</last_name>
    <role>Study Director</role>
    <affiliation>Seattle Genetics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seattle Genetics Trial Information Support</last_name>
    <phone>866-333-7436</phone>
    <email>clinicaltrials@seagen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chao Family Comprehensive Cancer Center University of California Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ritesh Parajuli</last_name>
      <phone>714-456-8614</phone>
      <email>rparajul@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Ritesh Parajuli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helen F. Graham Cancer Center / Christiana Care Health Systems</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise DeMaio</last_name>
      <phone>302-623-4500</phone>
      <email>denise.a.demaio@christianacare.org</email>
    </contact>
    <investigator>
      <last_name>Michael Guarino</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Institute of Florida</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Coakley</last_name>
      <phone>407-303-2070</phone>
      <email>susan.coakley@flhosp.org</email>
    </contact>
    <contact_backup>
      <last_name>Sara Guyler</last_name>
      <phone>407-303-2024</phone>
      <email>sara.guyler@flhosp.org</email>
    </contact_backup>
    <investigator>
      <last_name>Carlos Alemany</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute / Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renee Bent</last_name>
      <phone>404-778-1900</phone>
      <email>renee.bent@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Jane Meisel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ingalls Cancer Care / Ingalls Memorial Hospital</name>
      <address>
        <city>Harvey</city>
        <state>Illinois</state>
        <zip>60426</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Marriott</last_name>
      <phone>703-339-4800</phone>
      <email>mmarriott@ingalls.org</email>
    </contact>
    <contact_backup>
      <last_name>Amber Kindt</last_name>
      <phone>703-339-4800</phone>
      <email>akindt@ingalls.org</email>
    </contact_backup>
    <investigator>
      <last_name>Danielle Sterrenberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Tait</last_name>
      <phone>410-328-2703</phone>
      <email>ntait@umm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lindsey Vacovsky</last_name>
      <phone>410-328-2703</phone>
      <email>lindsey.vacovsky@umm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Katherine H. R. Tkaczuk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Piper Cancer Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacquelyn Underhill</last_name>
      <phone>612-863-4633</phone>
      <email>jacquelyn.underhill@allina.com</email>
    </contact>
    <contact_backup>
      <last_name>Lori Green</last_name>
      <phone>612-863-4633</phone>
      <email>lori.green@allina.com</email>
    </contact_backup>
    <investigator>
      <last_name>Michaela Tsai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Summit Medical Group</name>
      <address>
        <city>Florham Park</city>
        <state>New Jersey</state>
        <zip>07932</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Mackenzie</last_name>
      <phone>973-436-1755</phone>
      <email>mmackenzie@smgnj.com</email>
    </contact>
    <investigator>
      <last_name>Steven Papish</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Cancer Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karwyn Gustafson, MD</last_name>
      <phone>505-272-4946</phone>
      <email>ksgustafson@salud.unm.edu</email>
    </contact>
    <investigator>
      <last_name>Ursa Brown-Glaberman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hillman Cancer Center / University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Cieply</last_name>
      <phone>412-647-2811</phone>
      <email>cieplysl2@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Adam Brufsky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 30, 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2017</study_first_submitted>
  <study_first_submitted_qc>October 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2017</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Breast carcinoma</keyword>
  <keyword>Triple negative breast cancer</keyword>
  <keyword>Locally-advanced breast cancer</keyword>
  <keyword>Metastatic breast cancer</keyword>
  <keyword>Tumors, breast</keyword>
  <keyword>Breast tumors</keyword>
  <keyword>pembrolizumab</keyword>
  <keyword>LIV-1 protein, human</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Immunoconjugates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

